

IN VITRO* MAMMALIAN CELL MUTATION ASSAYS

C. ANITA H. BIGGER,¹ MARTHA M. MOORE,² AND
ROBERT H. HEFLICH²

¹*U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, Maryland*

²*U.S. Food and Drug Administration, National Center for Toxicological Research, Jefferson, Arkansas*

Contents

- 1 Introduction
- 2 Regulatory Guidances and Protocol Guidelines for *In Vitro* Mammalian Cell Mutation Assays
 - 2.1 Regulatory Guidances
 - 2.2 Protocol Guidelines
- 3 Endpoints and Unique Characteristics of *In Vitro* Mammalian Cell Mutation Assays
 - 3.1 Differences in the Spectra of Genetic Events Detected by *In Vitro* Mammalian Cell Mutation Assays
 - 3.2 Differences in the Spectra of Genetic Events Detected by the MLA, the *In Vitro* Chromosomal Aberrations Assays, and the Ames Test
 - 3.3 Correlation of *In Vitro* Mammalian Cell Mutation Assays with Rodent Bioassays
- 4 Criticisms of *In Vitro* Mammalian Cell Assays
 - 4.1 False Positives, High Concentrations, and Cytotoxicity Criteria
 - 4.2 Hazard Identification and Risk Assessment
- 5 Protocols for *In Vitro* Mammalian Cell Mutation Assays
 - 5.1 Commonalities and Differences in Protocols for *In Vitro* Mammalian Cell Mutation Assays
 - 5.2 Detailed Protocols
- References

*The views expressed in this chapter do not necessarily reflect FDA policy.

Pharmaceutical Sciences Encyclopedia: Drug Discovery, Development, and Manufacturing
Edited by Shayne C. Gad
Copyright © 2010 John Wiley & Sons, Inc.